Adiposogenital syndrome is a clinical condition characterized by the coexistence of obesity and hypogonadism, arising from dysfunction of the hypothalamus or pituitary gland. It is widely known in the literature as Fröhlich Syndrome, having been first described in 1901 by Austrian neurologist Alfred Fröhlich.

Pathophysiology

The core mechanism involves dysfunction or structural damage to the ventromedial and arcuate nuclei of the hypothalamus — regions that govern both energy balance and gonadotropin secretion. Hypothalamic injury leads to leptin resistance, suppression of GnRH secretion, and consequently deficient LH and FSH production. Mass lesions such as pituitary adenomas can produce the same picture through direct compression of these regulatory centers.

Causes

The principal factors implicated in the development of the syndrome include:

• Pituitary adenoma: The most frequently encountered cause; craniopharyngioma is particularly prominent in children
• Hypothalamic tumors: Germinoma, glioma, hamartoma
• Infiltrative diseases: Sarcoidosis, Langerhans cell histiocytosis, tuberculosis
• Trauma and surgery: Interventions involving the hypothalamic or pituitary region
• Idiopathic: Cases in which no underlying cause can be identified

Clinical Features

Beyond the two cardinal components of obesity and hypogonadism, a range of additional findings may be present:

• Obesity: Prominent fat deposition in the trunk, hips, and thighs, with the face, hands, and feet relatively spared
• Hypogonadism: Small testes and penile underdevelopment in males; amenorrhea and absent breast development in females
• Growth retardation: Short stature and delayed skeletal maturation in children
• Polyuria and polydipsia: Diabetes insipidus may accompany the syndrome
• Visual disturbances: Visual field defects secondary to mass compression
• Behavioral changes: Apathy and cognitive slowing

Diagnosis

Diagnosis is established through the integrated assessment of clinical findings, biochemical testing, and imaging. Basal and stimulated LH, FSH, and sex steroid levels that are consistently low support the diagnosis of hypogonadotropic hypogonadism. Pituitary MRI is the primary imaging modality for detecting mass lesions. Bone age assessment reflects skeletal maturation in pediatric patients. The differential diagnosis must include Prader-Willi syndrome, Laurence-Moon-Biedl syndrome, and simple obesity.

Treatment

The therapeutic approach is tailored according to the underlying cause and the patient’s age.

• Mass lesions: Surgical resection with radiotherapy where indicated
• Hormone replacement: Sex steroid replacement for hypogonadism; growth hormone therapy in cases of GH deficiency
• Diabetes insipidus: Management with desmopressin (DDAVP)
• Obesity: Dietary modification, behavioral interventions, and structured physical activity programs

Prognosis

Prognosis depends largely on the treatability of the underlying cause. In benign tumors such as craniopharyngioma, early surgical intervention may partially correct hormonal deficits; however, when hypothalamic damage is permanent, hypogonadism and metabolic disturbances may persist lifelong. Regular endocrinological follow-up and a multidisciplinary care approach are essential for preserving quality of life.